Please assess the completion status of the following clinical trial:

Trial Title: Statins for Acutely Injured Lungs From Sepsis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 1. Systemic inflammatory response syndrome (SIRS) defined as meeting at least criteria (a) or (b)for a systemic inflammatory response:~  1. White blood cell count \>12,000 or \<4,000 or \>10% band forms~ 2. Body temperature \>38 degrees Celsius (C) (any route) or \<36 degrees C (accepting core temperatures only; indwelling catheter, esophageal, rectal)~ 3. Heart rate (\> 90 beats/min) or receiving medications that slow heart rate or paced rhythm 2. Suspected or proven infection: Sites of infection include thorax, urinary tract, abdomen, skin, sinuses, central venous catheters, and bacterial meningitis (Appendix A).~     3. ALI as defined by acute onset of:~  <!-- -->~  1. PaO2 / FiO2 ≤ 300 (intubated). If altitude \> 1000m, then PaO2 / FiO2 ≤ 300 x (PB/760), and~ 2. Bilateral infiltrates consistent with pulmonary edema on frontal chest radiograph, and~ 3. Requirement for positive pressure ventilation via an endotracheal tube, and~ 4. No clinical evidence of left atrial hypertension, or if measured, a Pulmonary Arterial Wedge Pressure (PAOP) less than or equal to 18 mm Hg. If a patient has a PAOP \> 18 mmHg, then the other criteria must persist for more than 12 hours after the PAOP has declined to ≤ 18 mmHg, and still be within the 48-hour enrollment window.~Acute onset is defined as follows: the duration of the hypoxemia criterion (#1) and the chest radiograph criterion (#2) must be ≤ 28 days at the time of randomization. Opacities considered consistent with pulmonary edema include any patchy or diffuse opacities not fully explained by mass, atelectasis, or effusion or opacities known to be chronic (\> 28 days). The findings of vascular redistribution, indistinct vessels, and indistinct cardiac borders are not considered consistent with pulmonary edema.~All ALI criteria (3a-d above) must occur within the same 24 hour period. The onset of ALI is when the last ALI criterion is met. Patients must be enrolled within 48 hours of ALI onset and no more than 7 days from the initiation of mechanical ventilation. SIRS criteria must occur within the 72 hours before or the 24 hours after ALI onset. Information for determining when these time window criteria were met may come from either the Network hospital or a referring hospital reports.~Exclusion Criteria:~1. No consent/inability to obtain consent~2. Age less than 18 years~3. More than 7 days since initiation of mechanical ventilation~4. More than 48 hours since meeting ALI inclusion criteria~5. Patient, surrogate, or physician not committed to full support ).~6. Unable to receive or unlikely to absorb enteral study drug~7. Rosuvastatin specific exclusions~   * Receiving a statin medication within 48 hours of randomization~  * Allergy or intolerance to statins~  * Physician insistence for the use or avoidance of statins during the current hospitalization~  * Creatine Kinase (CK) , alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 5 times the upper limit of normal~  * Diagnosis of hypothyroidism and not on thyroid replacement therapy~  * Pregnancy or breast feeding~  * Receiving niacin, fenofibrate or cyclosporine, gemfibrozil, atazanavir, lopinavir, ritonavir, daptomycin~8. Severe chronic liver disease~9. Moribund patient not expected to survive 24 hours~10. Chronic respiratory failure defined as PaCO2 \> 60 mm Hg in the outpatient setting~11. Home mechanical ventilation (noninvasive ventilation or via tracheotomy) except for CPAP/BIPAP (Continuous Positive Airway Pressure/BiLevel Positive Airway Pressure) used solely for sleep-disordered breathing~12. Diffuse alveolar hemorrhage from vasculitis~13. Burns \> 40% total body surface~14. Interstitial lung disease of severity sufficient to require continuous home oxygen therapy~15. Unwillingness or inability to utilize the ARDS network 6 ml/kg Predicted Body Weight (PBW) ventilation protocol~16. Cardiac disease classified as NYHA (New York Heart Association) class IV~17. Myocardial infarction within past 6 months~18. Intraparenchymal Central Nervous System (CNS) bleed within a month of randomization.~19. Temperature \>40.3 C in the 6 hours before randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rosuvastatin (Type: ACTIVE_COMPARATOR): Half of the subjects were randomized to the active drug (Rosuvastatin).~Dosage, Form, and Frequency: drug was provided as 10mg tablets and administered through an enteral feeding tube or orally (following extubation when patients were able to safely take oral medications). An initial 40mg loading dose was administered followed by a daily 20 mg maintenance dose. Maintenance dosing was adjusted for renal failure not compensated by renal replacement therapy.~Duration: drug was administered daily until:~1. 28 days after randomization or 3 days after ICU discharge (whichever comes first),~2. Discharge from study hospital,~3. Death
- Placebo (Type: PLACEBO_COMPARATOR): Half of the subjects were randomized to placebo.~10mg tablets identical to active drug were administered through an enteral feeding tube or orally (following extubation when patients were able to safely take oral medications). Dosage, frequency, and duration was provided in the same manner as the active drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).